CVS CEO says GLP-1 ‘economics simply aren’t there yet’ for employers: Washington Post
AI Summary
CVS Health CEO David Joyner expresses doubt about the economic viability of GLP-1 medications for employers, citing a lack of evidence showing that the long-term health benefits justify today's high costs. His comments highlight a critical debate on whether the savings from preventing future health issues can offset current expenses. This skepticism is significant as it influences employer decisions on health benefits and drug coverage, potentially impacting broader healthcare economics and patient care.
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.